Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555814 | 0.89 | CYP3A4 (0.48) | CYP3A4USP2MAPK1SMN1; SMN2ERN1 | |
| SCHEMBL3559875 | 0.88 | MAOB (0.46) | CYP3A4USP2MAPK1SMN1; SMN2ERN1 | |
| SCHEMBL3557737 | 0.87 | ALDH1A1 (0.41) | CYP3A4USP2MAPK1SMN1; SMN2ERN1 | |
| SCHEMBL3559775 | 0.82 | CYP3A4 (0.48) | CYP3A4MAOBPOLBGAAMAPT | |
| SCHEMBL3553661 | 0.81 | FFAR4 (0.42) | CYP3A4USP2MAPK1SMN1; SMN2ERN1 | |
| SCHEMBL3555769 | 0.76 | ERN1 (0.57) | CYP3A4USP2MAPK1SMN1; SMN2ERN1 | |
| SCHEMBL3558547 | 0.72 | ACHE (0.46) | CYP3A4USP2MAPK1SMN1; SMN2ERN1 | |
| SCHEMBL4445709 | 0.71 | CYP3A4 (0.59) | CYP3A4USP2MAPK1SMN1; SMN2ERN1 | |
| SCHEMBL3557567 | 0.71 | CYP3A4 (0.36) | CYP3A4HPGDGAAKMT2AMEN1 | |
| SCHEMBL28370780 | 0.71 | CYP3A4 (0.76) | CYP3A4USP2MAPK1SMN1; SMN2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662826-B2 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD. (JP) | 2010-02-16 | — | — | US | disclosed |
| US-20060089362-A1 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | SHIONOGI & CO., LTD (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1505068-A1 | PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1155698-A1 | ORGANOBORON COMPOUNDS EXHIBITING ANTICOCCIDIAL ACTIVITIES | Nitto Kasei Co., Ltd. (JP) | 2001-11-21 | — | — | EP | disclosed |
| EP-1057825-A1 | ISOFLAVANE DERIVATIVES AND IMMUNOPOTENTIATING COMPOSITIONS CONTAINING THE SAME | SHIONOGI & CO., LTD. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089362-A1 | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same | NADK, PNPO, NQO1 | CYP3A4 300/4885USP2 4556/4885MAPK1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.